Choice of frst drug of genetically engineered therapy: Benefts of guselcumab

L. S. Kruglova; E. A. Shatokhina; A. S. Polonskaya; A. Yu. Syryseva

Medical alphabet
Medicinskij alfavit

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

User

eng | рус

Medical alphabet

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Kruglova L.S., Shatokhina E.A., Polonskaya A.S., Syryseva A.Yu. Choice of frst drug of genetically engineered therapy: Benefts of guselcumab. Medical alphabet. 2022;(8):48-55. (In Russ.) https://doi.org/10.33667/2078-5631-2022-8-48-55

Views PDF (Rus): 100

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles Editors' Choice

Editor-in-Chief

Petrikov Sergey S.

Subscription Login to verify subscription

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

L. S. Kruglova
Central State Medical Academy
Russian Federation

Kruglova Larisa S., DM Sci (habil.), professor, vice-rector for academic affairs, head of Dept of Dermatovenereology and Cosmetology

SPIN: 1107–4372

E. A. Shatokhina
Central State Medical Academy
Russian Federation

Shatokhina Evgenia A., DM Sci (habil.), associate professor, professor at Dept of Dermatovenereology and Cosmetology

A. S. Polonskaya
Central State Medical Academy
Russian Federation

Polonskaya Aleksandra S., post-graduate student of Dept of Dermatovenereology and Cosmetology

A. Yu. Syryseva
Central State Medical Academy
Russian Federation

Syryseva Anastasia Yu., resident of the 1st year of Dept of Dermatovenereology and Cosmetology

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical alphabet

For citations:

Cookies policy